阿巴西普治疗类风湿关节炎患者接种重组带状疱疹疫苗的安全性与免疫原性
这项多中心双盲随机对照试验将70例使用阿巴西普的类风湿关节炎患者随机分配接种2剂重组带状疱疹疫苗或安慰剂,间隔8周。结果显示疫苗安全性良好、RA flare率与安慰剂组相似,但体液和细胞免疫应答均减弱,仅42.3%达到4倍抗体升高阈值、10.2%产生细胞应答。
要点
- 使用阿巴西普的RA患者接种RZV安全,RA flare率与安慰剂组相似(68% vs 64%)。
- 疫苗免疫原性减弱:仅42.3%达体液应答阈值,仅10.2%产生细胞应答。
- 抗gE IgG的GMFR为4.55(3.16, 6.47),提示体液应答有限。
核心结论
- 在应用阿巴西普的类风湿关节炎患者中,重组带状疱疹疫苗安全性良好,但疫苗应答减弱。
- 建议进一步研究疫苗接种前后暂停阿巴西普是否可改善疫苗应答。
研究设计与样本
- 多中心、双盲、随机对照预试验,共随机70例使用阿巴西普的类风湿关节炎患者。
- 受试者随机接受2剂重组带状疱疹疫苗或安慰剂,间隔8周。
- 主要免疫学终点为第12周(第二剂后4周)体液应答(抗gE IgG≥4倍升高)和细胞应答(IFN-γ+或IL-2+ gE特异性斑点形成细胞≥2倍升高)的比例。
主要发现
- 接受RZV者中仅22例(42.3%)超过体液应答4倍阈值,抗gE IgG第12周GMFR为4.55(3.16, 6.47)。
- 仅5例(10.2%)接受RZV者产生细胞应答。
- 共记录6例严重不良事件;RZV组与安慰剂组RA flare比例相似(38例[68%] vs 9例[64%])。
关键数值与推荐
- 体液应答定义为抗gE IgG较基线≥4倍升高;细胞应答定义为IFN-γ+或IL-2+ gE特异性斑点形成细胞≥2倍升高。
- RA flare通过DAS28-ESR、CDAI和OMERACT RA-FQ评分评估。
临床怎么用
- 使用阿巴西普的RA患者可安全接种RZV,但需预期免疫应答可能减弱。
- 接种前后是否暂停阿巴西普以改善疫苗应答尚需进一步研究,目前不应据此改变临床决策。
局限性
- 为预试验,样本量较小(70例),结果需更大规模研究验证。
- 未评估暂停阿巴西普对疫苗应答的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The objective of the study is to evaluate the safety and immunogenicity of the recombinant zoster vaccine (RZV) in patients with rheumatoid arthritis (RA) using abatacept. METHODS: We randomised 70 participants to receive 2 doses of RZV or placebo 8 weeks apart. The primary immunologic endpoint was the proportion of participants developing a ≥4-fold increase in anti-glycoprotein E (gE) immunoglobulin (Ig)G antibodies (humoral responders) and those developing a ≥2-fold increase in interferon gamma (IFN-γ)+ or interleukin-2 (IL-2)+ gE-specific spot-forming cells (cellular responders), at week 12 (ie, 4 weeks post-second RZV dose). The secondary immunologic endpoint was the geometric mean fold rise (GMFR) in cellular and humoral vaccine responses. For safety, we solicited adverse events following each dose, serious adverse events (SAEs) during the 52-week study period, and evaluated the potential for RA flares by assessing pre- and postvaccination Disease activity score-28 for rheumatoid arthritis with erythrocyte sedimentation rate, Clinical Disease Activity Index (CDAI), and Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis flare questionnaire (RA-FQ) scores. RESULTS: Fifty-six (75%) participants received RZV, and 14 (25%) received a placebo. Among those receiving RZV, only 22 (42.3%) of participants surpassed the 4-fold threshold for humoral response, and anti-gE IgG GMFR at week 12 was 4.55 (3.16, 6.47). Only 5 (10.2%) patients with RZV mounted cellular responses. Six SAEs were noted, and the proportion of patients with RA flare was similar between RZV and placebo groups (38 [68%] vs 9 [64%]). CONCLUSIONS: Our data suggest that RZV is safe in patients with RA using abatacept, but that the vaccine response is attenuated in such patients. Further studies should be undertaken to evaluate whether holding abatacept around the time of vaccination would improve vaccine response.
引用
- Hawkins JA, Curtis JR, Weinberg A, et al. Safety and immunogenicity of the recombinant zoster vaccine in patients with rheumatoid arthritis using abatacept: a pilot multicentre, double-blind, randomised controlled trial. Ann Rheum Dis. 2026. PMID: 41672807. doi:10.1016/j.ard.2026.01.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。